Stock traders buy large volume of Sanofi call options (NASDAQ:SNY)
Sanofi Inc (NASDAQ:SNY – Get Rating) was the recipient of some unusual options trades on Thursday. Investors bought 6,886 call options on the stock. This represents a 1,182% increase from the typical volume of 537 call options.
Sanofi shares down 4.2%
NASDAQ: SNY fell $1.90 in Thursday’s midday session, hitting $43.30. The stock had a trading volume of 437,535 shares, compared to an average volume of 1,683,586. The company has a market capitalization of $109.59 billion, a price-earnings ratio of 15.02, a price ratio /growth earnings of 1.16 and a beta of 0.48. Sanofi has a 1-year low of $43.20 and a 1-year high of $58.10. The stock’s 50-day simple moving average is $50.42 and its two-hundred-day simple moving average is $51.99. The company has a debt ratio of 0.22, a current ratio of 1.29 and a quick ratio of 0.34.
Hedge funds weigh on Sanofi
A number of hedge funds have been buying and selling SNY shares recently. GHP Investment Advisors Inc. bought a new position in Sanofi in the first quarter worth approximately $26,000. Fairfield Bush & CO. bought a new equity stake in Sanofi during the first quarter valued at approximately $26,000. Pinnacle Bancorp Inc. increased its stake in Sanofi by 49.0% during the first quarter. Pinnacle Bancorp Inc. now owns 587 shares of the company worth $30,000 after buying 193 additional shares in the last quarter. Ahrens Investment Partners LLC acquired a new stake in Sanofi during the first quarter for a value of approximately $31,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in Sanofi in the first quarter worth approximately $32,000. 12.82% of the shares are currently held by institutional investors and hedge funds.
Wall Street analysts predict growth
Several brokerages have recently released reports on SNY. Credit Suisse Group raised its price target on Sanofi from €105.00 ($107.14) to €110.00 ($112.24) and gave the company an “outperform” rating in a report by the Friday July 22. JPMorgan Chase & Co. raised its price target on Sanofi from €105.00 ($107.14) to €115.00 ($117.35) in a Monday, August 1 report. Deutsche Bank Aktiengesellschaft raised its price target on Sanofi from €85.00 ($86.73) to €90.00 ($91.84) and gave the company a “sell” rating in a report from the Friday July 29. UBS Group downgraded Sanofi from a “buy” rating to a “neutral” rating in a research note on Tuesday. Finally, Morgan Stanley raised its price target on Sanofi from €110.00 ($112.24) to €112.00 ($114.29) in a Friday, April 22 research note. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and six has assigned the stock a buy rating. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $111.14.
(Get an assessment)
Sanofi, together with its subsidiaries, is engaged in the research, development, manufacturing and marketing of therapeutic solutions in the United States, Europe and internationally. It operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology and rare blood disorders; diabetes medication; and cardiovascular and established prescription products.
This instant news alert was powered by MarketBeat’s storytelling science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]
Before you consider Sanofi, you’ll want to hear this.
MarketBeat tracks daily the highest rated and most successful research analysts on Wall Street and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes off…and Sanofi wasn’t on the list.
While Sanofi currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
See the five actions here